RALEIGH, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that one of its stockholders, consisting of an affiliate of, or a fund sponsored [...]
See the latest interactions from our social media
The molecule, called vascin, penetrates cancer cells and causes VEGFR2 to clump up and become crippled.
Read the latest updates from our PR department
$399.8 million of service revenue in the third quarter; 16.0% constant currency growth compared to the third quarter of 2015 Third quarter GAAP Net Income per diluted share increased 32.4% to $0.49 [...]
RALEIGH, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.